Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Pfizer’s Xeljanz pill has been approved in the US in psoriatic arthritis, for people who have not responded to, or cannot take, other disease-modifying drugs. Xeljanz has been FDA-approved since ...

There are dozens of medications available ... help relieve some arthritis symptoms. Approved to treat certain forms of inflammatory arthritis such as psoriatic arthritis, rheumatoid arthritis ...

“This FDA approval indicates global ... a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

A new oral treatment for psoriatic arthritis ... this will boost its revenues. The drug was filed in Europe in January this year, with a European approval launch anticipated therefore expected ...

This article explains why PD sometimes can be challenging to manage, describes the medications approved to treat ... for ...

UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Bimzelx is now approved for the treatment of adult patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. The Food and Drug Administration (FDA ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.